Summit Therapeutics annual operating margin
2018
2019
2020
2021
2022
Summit Therapeutics Operating Margin Growth & History (SMMT)
Summit Therapeutics's operating margin was −10,225.39% for fiscal 2022.
View full Summit Therapeutics company overviewSummit Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −10,225.39% | −5461.10 pp |
| 2021 | 2021-12-31 | −4,764.29% | +1420.94 pp |
| 2020 | 2020-12-31 | −6,185.23% | −2487.66 pp |
| 2019 | 2019-12-31 | −3,697.58% | — |
| 2018 | 2019-01-31 | 9.44% | — |
Summit Therapeutics quarterly operating margin
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q3 2022 | 2022-09-30 | −7,700.00% | −6211.38 pp |
| Q2 2022 | 2022-06-30 | −5,400.85% | +36230.73 pp |
| Q1 2022 | 2022-03-31 | −8,863.20% | −49.14 pp |
| Q4 2021 | 2021-12-31 | −10,377.29% | −4130.80 pp |
| Q3 2021 | 2021-09-30 | −1,488.62% | +7871.05 pp |
| Q2 2021 | 2021-06-30 | −41,631.58% | −32598.64 pp |
| Q1 2021 | 2021-03-31 | −8,814.06% | −5931.35 pp |
| Q4 2020 | 2020-12-31 | −6,246.49% | — |
| Q3 2020 | 2020-09-30 | −9,359.67% | −5177.24 pp |
| Q2 2020 | 2020-06-30 | −9,032.94% | — |
| Q1 2020 | 2020-03-31 | −2,882.72% | — |
| Q3 2019 · Sep 30 | 2019-09-30 | −4,182.43% | — |
Summit Therapeutics operating margin trends
Between the periods ended 2019-01-31 and 2022-12-31, Summit Therapeutics's operating margin decreased from 9.44% to −10,225.39%, a change of −10234.83 percentage points. The latest reported quarter, Q3 2022, shows −7,700.00%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Summit Therapeutics source filings ↗Community posts
AstraZeneca commits $2 billion to Summit alongside cancer-trial collaboration
AstraZeneca ($AZN) has agreed to invest $2 billion in Summit Therapeutics ($SMMT) through preferred shares convertible into common stock at an effective $18.36 per share. Approximately 108,955 preferred shares would each convert into 1,000 ...
